" /> Eganelisib - CISMeF





Preferred Label : Eganelisib;

NCIt definition : An orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile.;

UNII : FOF5155FMZ;

InChIKey : XUMALORDVCFWKV-IBGZPJMESA-N;

CAS number : 1693758-51-8;

Molecule name : IPI 549; IPI-549;

NCI Metathesaurus CUI : CL504218;

Details


You can consult :


Nous contacter.
09/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.